Gottlieb's 2018 Generic Drug Approval Goal May Be In Doubt
Thanks in large part to new elemental impurities requirements, ANDA approvals are behind the pace needed to beat 2017’s record.
You may also be interested in...
Talks remain in early stages, but both sides thinking 'outside the box' to come up with potential policy updates to generate more generic competition and bring down drug prices.
Bringing the hammer down on biopharma, HHS Secretary Azar says department could use demonstration projects to switch drugs from Medicare Part B to Part D.
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.